AKT1 and Alzheimer disease: In addition, we identified the main signaling pathways involved in the treatment of KOA by KEGG enrichment analysis, and screened the first 20 pathways related to KOA and significantly enriched (FDR < 0.05), including Pathways of neurodegeneration - multiple diseases (hsa05022), Alzheimer disease (hsa05010), Lipid and atherosclerosis (hsa05417), Neuroactive ligand–receptor interaction (hsa04080), MAPK signaling pathway (hsa04010), PI3K–AKT pathway (hsa04151) among others.